

ALLERGAN INC  
Form DEFA14A  
September 29, 2014

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**September 29, 2014**

**Date of Report (Date of Earliest Event Reported)**

**ALLERGAN, INC.**

**(Exact Name of Registrant as Specified in its Charter)**

|  |                                 |                               |
|--|---------------------------------|-------------------------------|
| <b>Delaware</b>  | <b>1-10269</b>                  | <b>95-1622442</b>             |
| <b>(State of Incorporation)</b>                            | <b>(Commission File Number)</b> | <b>(IRS Employer</b>          |
|  | <b>2525 Dupont Drive</b>        | <b>Identification Number)</b> |
|  | <b>Irvine, California 92612</b> |                               |
| <b>(Address of Principal Executive Offices) (Zip Code)</b> |                                 |                               |
|  | <b>(714) 246-4500</b>           |                               |

**(Registrant's Telephone Number, Including Area Code)**

N/A

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01. Other Events.**

On September 29, 2014, Allergan, Inc. ( Allergan ) issued a press release regarding a statement issued by Allergan's Board of Directors addressing recent market speculation regarding Allergan. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

On September 29, 2014, Allergan also issued a press release announcing U.S. Food and Drug Administration approval of OZURDEX® (dexamethasone intravitreal implant) 0.7 mg, a sustained-release biodegradable steroid implant, for the treatment of diabetic macular edema. A copy of the press release is attached as Exhibit 99.2 to this Current Report on Form 8-K.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

99.1 Allergan, Inc. Board of Directors statement press release dated September 29, 2014

99.2 Allergan, Inc. FDA approval press release dated September 29, 2014

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ALLERGAN, INC.**

Date: September 29, 2014

By: /s/ Matthew J. Maletta  
Name: Matthew J. Maletta  
Title: Vice President,  
Associate General Counsel and Secretary

**Exhibit Index**

| <b>Exhibit</b> | <b>Description of Exhibit</b>   |
|----------------|---|
| 99.1           | Allergan, Inc. Board of Director statement press release dated September 29, 2014 |
| 99.2           | Allergan, Inc. FDA approval press release dated September 29, 2014                |